Delayed start, rapid solution?

Neuroepidemiology

Volumn 35, Issue 3, 2010, Pages 214-

  Korczyn, Amos D ^a   Vakhapova, Veronika ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

RASAGILINE;

ALZHEIMER DISEASE; COGNITION; DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; HUMAN; MENTAL HEALTH; MOTOR DYSFUNCTION; NEUROPROTECTION; NOTE; PARKINSON DISEASE; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE;

ALZHEIMER DISEASE; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 77958077943     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316647     Document Type: Note

References (3)

1. Poewe WH, Wenning GK: The natural history of Parkinson's disease. Neurology 1996; 47(suppl 3):S146-S152.
2. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators: A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-1278.
3. Vanacore N: What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson's disease? Neuroepidemiology 2010;35:213.